Page last updated: 2024-08-20

nafcillin and norfloxacin

nafcillin has been researched along with norfloxacin in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Apiwattanakul, N; Endou, H; Jariyawat, S; Kanai, Y; Sekine, T; Sophasan, S; Takeda, M1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Blango, MG; Mulvey, MA1
Bohnert, JA; Karamian, B; Nikaido, H1
Anderson, KC; Kellogg, GE; Sarkar, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for nafcillin and norfloxacin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for nafcillin and norfloxacin

ArticleYear
The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 290, Issue:2

    Topics: Animals; Anion Transport Proteins; Anti-Bacterial Agents; Biological Transport; Carrier Proteins; Cell Survival; Cephaloridine; Cephalosporins; In Vitro Techniques; Kidney; Kinetics; Oocytes; p-Aminohippuric Acid; Penicillin G; Rats; Recombinant Proteins; Xenopus laevis

1999
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistance, Bacterial; Endosomes; Escherichia coli; Escherichia coli Infections; Female; Humans; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Recurrence; Urinary Bladder; Urinary Tract Infections; Urothelium

2010
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:9

    Topics: Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chlortetracycline; Dipeptides; Doxorubicin; Doxycycline; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Minocycline; Onium Compounds; Organophosphorus Compounds; Tetracycline

2010
Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
    European journal of medicinal chemistry, 2012, Volume: 52

    Topics: Anti-Bacterial Agents; beta-Lactams; Computational Biology; Drug Resistance, Bacterial; Hydrophobic and Hydrophilic Interactions; Ligands; Membrane Transport Proteins; Microbial Sensitivity Tests; Models, Molecular; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Regression Analysis; Thermodynamics

2012